Integrating cold chain pharmaceutical products into the Expanded Program on Immunization (EPI) supply chain has been a topic of interest for several years based on potential efficiencies from using the same cold storage and distribution system, and the availability of a growing number of temperature-sensitive pharmaceutical products. The integration of oxytocin into the cold chain has been noted as one product that could deliver notable public health benefits. Although endorsed by global bodies such as WHO and UNICEF, the integration of oxytocin into vaccine cold chain at the facility level has not been taken up systematically. This brief provides guidance to national level EPI and maternal health decision makers to help address the low-hanging fruit of including oxytocin in the CCE at the facility level and provides evidence to address perceived barriers to integration, and highlights key considerations for successfully integrating oxytocin.